Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-30 01:02:03 - browse：91

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Novo Nordisk to buy Cardior, building up pipeline of heart drugs

WSS

'Patient friction coefficient' can gauge a clinical trial's patient burden

Mirador, a new biotech startup, launches with $400 million

Pfizer, Moderna say biotech, pharma drug development is a sprint

Readout Newsletter: Illumina, CRISPR, Regeneron

Pregnancy ages women, but effects reverse after delivery

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Wikipedia

Wikipedia

hotspot

New air purifier tech could be key to improving indoor air quality

Idaho abortion case may prompt more restrictions in other states

Peter Hotez and the public health issue of online harassment

Diabetes management: Digital health tools fall short, study says

At least 13 dead in Texas as scorching temps continue

U.K. officials, researchers try to ease path for bespoke genetic treatments

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Illumina, CRISPR, Regeneron

Medical leaders decry Supreme Court decision on affirmative action

New Medicare drug pricing powers could soon be upended in court

hotspot

Doulas covered by Medicaid under New York's new plan

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Medical devices makers are asking for forgiveness, not permission

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

6 surprising facts about sugar

Wikipedia

explore

explore

knowledge